• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J’s Ethicon launches Vistaseal fibrin sealant

December 3, 2019 By Sean Whooley

EthiconJohnson & Johnson (NYSE:JNJ) subsidiary Ethicon announced today that it launched its Vistaseal fibrin sealant for managing bleeding during surgery.

The sealant system is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard techniques (suture, ligature, cautery) are ineffective or impractical.

Vistaseal fibrin sealant consists of a combination of fibrinogen and thrombin, which are clotting proteins found in human plasma. It is designed to form a rapid, adherent and durable clot and sustain hemostasis, even in high-risk patients, when applied to the bleeding site.

Ethicon said Vistaseal, which comes in pre-filled syringes, is the first fibrin sealant exclusively designed to be sprayed without gas in open and minimally invasive procedures, eliminating steps required for set-up and potentially saving valuable time in the operating room.

In three randomized controlled trials, the sealant was associated with a lower overall hemostatic retreatment rate (0.9% to 7.8%) when compared to standard treatments (8% to 16.7%), according to a news release.

Vistaseal is the first product to come out of a strategic partnership between Ethicon and Grifols (NSDQ:GRFS), which developed the sealant and licensed it to Ethicon. In June, Ethicon won FDA clearance for its airless spray devices to deliver Grifols’ fibrin sealant to stop surgical bleeding.

“Surgical patients often present with multiple risk factors such as coagulopathies, uncontrolled diabetes, renal or liver failure or are taking anticoagulants or chronic antiplatelet therapies that may interfere with the body’s natural ability to form a clot, which increases the risk of surgical bleeding,” Henry Ford Hospital director of surgical oncology Dr. David Kwon said in the release. “Vistaseal has the potential to offer a rapid, adherent, durable clot even in my most demanding cases.”

“Vistaseal is the latest addition to our broad portfolio of primary and adjunctive hemostat solutions that address the growing and wide-ranging challenges surgeons face in managing bleeding,” added Ethicon president of global biosurgery Oray Boston. “We will continuously aim to advance the standard of care in surgery to better serve health care professionals and improve outcomes for patients.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Hematology, Surgical Tagged With: Ethicon, Grifols

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS